> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# New Indication for Vanda’s Fanapt
- URL: https://www.fdaweb.com/new-indication-for-vandas-fanapt/
- Published: 2024-04-03T12:00:00.000Z
- Updated: 2026-09-14T14:27:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156694

FDA has approved a new indication for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults for Vanda Pharmaceuticals’ Fanapt (iloperidone). A company statement [says](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-fanapt-iloperidone-receives-us-fda-approval-for-the-acute-treatment-of-bipolar-i-disorder-302106405.html?ref=fdaweb.com#:~:text=WASHINGTON%2C%20April%202%2C%202024%20%2F,bipolar%20I%20disorder%20in%20adults.) Fanapt is an atypical antipsychotic agent that has been used for the acute treatment of patients with schizophrenia since its FDA approval in 2009.

Fanapt’s approval for the new indication was based on a study of some 400 patients.